Adenovirus Specific T- Lymphocytes
Cytomegalovirus Infection
Explore 10 assets in Cytomegalovirus Infection →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Jessie L. Alexander
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06909110CT.gov Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity | — | Recruiting | — | — | — |
NCT04364178CT.gov Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cytomegalovirus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adenovirus Specific T- Lymphocytes (this asset) | Jessie L. Alexander | P1/2 | CCC · 48 |
| Foscarnet | City of Hope Medical Center | P4 | BB |
| Valganciclovir | The Methodist Hospital Research Institute | P3 | BB |
| Ganciclovir | City of Hope Medical Center | P3 | BB |
| Cmvpp65-A*0201 Peptide Vaccine | City of Hope Medical Center | P2 | B |
| Letermovir | Fernanda P Silveira, MD, MS | P2 | B |
| Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine | City of Hope Medical Center | P2 | CCC |
| Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes | M.D. Anderson Cancer Center | P2 | CCC |
| Maribavir | Seoul National University Hospital | P2 | CCC |
+5 more in the Cytomegalovirus Infection cohort
Other indications for Adenovirus Specific T- Lymphocytes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adenoviridae Infectious Disease | — | P1/2 | CCC · 48 |
| Epstein-Barr Virus Infection | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adenovirus Specific T- Lymphocytes in Cytomegalovirus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adenovirus-specific-t-lymphocytes-cytomegalovirus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →